Tacalyx

Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility of synthesizing these complex structures allows the production of specific antibodies for the treatment of currently unsatisfactorily treatable cancers.

Info & Contact

Peter Sondermann
Web:
tacalyx.com

Address

Tacalyx GmbH
c/o Bayer CoLaborator (Gebäude S141)
Müllerstr. 178
13353 Berlin
Germany

In portfolio

02. Jul 2019